Wells Fargo lowered the firm’s price target on Agilon Health (AGL) to $1.50 from $5 and keeps an Overweight rating on the shares. The firm is updating estimates and price targets in the space ahead of Q3 2025 results. Notability, Wells now assumes extension of enhanced subsidies is likely.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Positive Outlook for Agilon Health: Buy Rating Driven by Macroeconomic Improvements and Strategic Initiatives
- Balanced Outlook for Agilon Health Amid Market Stability and Challenges
- Agilon Health downgraded to Market Perform from Outperform at Bernstein
- Agilon Health Faces Leadership and Performance Challenges Amid Hold Rating
- Agilon Health price target lowered to $1.10 from $2.40 at Jefferies